In two recent phase 2 trials designed for TP53 mutated myelodysplastic syndrome or AML, eprenetapopt combined with azacitidine induced an overall response rate of 62%–71% (44%–47% CR) with a median duration of response at 8–10.4 months. This evidence concerns the gene TP53 and acute myeloid leukemia.